PD-L1 testing, fit for routine evaluation? From a pathologist's point of view [0.03%]
PD-L1检测，适合常规评估吗？病理学家的视角
Georg Hutarew
Georg Hutarew
Tumours with high somatic mutation rates escape immune surveillance by upregulating receptors and ligands such as programmed death receptor-1 and its ligand (PD-1/PD-L1). Checkpoint inhibitors (ICI) provide encouraging therapeutic results i...
Short overview on the current treatment of chronic myeloid leukemia in chronic phase [0.03%]
慢性期慢性髓性白血病的治疗现状简述
Stefan Schmidt
Stefan Schmidt
This short review on current treatment options in chronic myeloid leukemia (CML) in the chronic phase summarizes the latest version of the ELN treatment recommendations dating from 2013 and indicates treatment situations not yet reflected i...
Alexander Reinthaller
Alexander Reinthaller
Angiogenesis plays a pivotal role in normal ovarian physiology as well as in the formation and progression of ovarian cancer. Several well-designed phase II and III trials studied the efficacy of antiangiogenic agents in advanced ovarian ca...
Reversal of direct oral anticoagulants in hemophilia treatment: ASH meeting 2015 [0.03%]
口服抗凝剂在血友病治疗中的逆转：ASH 会议 2015年回顾
Clemens Feistritzer,Stefan Schmidt
Clemens Feistritzer
During the 57th annual meeting of the American Society of Hematology 2015 in Orlando, Florida, various aspects in the field of hemostaseology were presented. The Choosing Wisely® campaign pointed out the importance of the critical use of d...
Lukas Weiss,Florian Huemer,Brigitte Mlineritsch et al.
Lukas Weiss et al.
Increased numbers of tumour infiltrating T‑cells have long been associated with a better prognosis in ovarian cancer, which has led to the general assumption of a relevant impact of T‑cellular anti-tumour immunity in this disease. As a co...
Simon Peter Gampenrieder,Gabriel Rinnerthaler,Richard Greil
Simon Peter Gampenrieder
Endocrine therapy represents the basis for the treatment of estrogen receptor-positive breast cancer, but several tumors harbor intrinsic resistance and acquired resistance to endocrine therapy is inevitable in metastatic disease. Combinati...
Thorsten Fuereder
Thorsten Fuereder
Over the past years immuno-oncology has evolved and become a novel promising strategy for cancer therapy. Immune checkpoint inhibitors such as pembrolizumab or nivolumab, which target the interaction between programmed death receptor 1/prog...
Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option [0.03%]
长效干扰素-α治疗毛细胞白血病：仍是一种可行的治疗选择
Jan-Paul Bohn,Guenther Gastl,Michael Steurer
Jan-Paul Bohn
Classic hairy cell leukemia (HCL) is a rare indolent B‑cell-lymphoproliferative disorder, first described as a distinct disease entity in 1958. After more than two decades without effective chemotherapeutic options and a dismal prognosis o...
Intensive care for cancer patients: An interdisciplinary challenge for cancer specialists and intensive care physicians [0.03%]
肿瘤患者的重症监护：肿瘤专科医生和重症医师的跨学科挑战
Peter Schellongowski,Michael Kiehl,Matthias Kochanek et al.
Peter Schellongowski et al.
Every sixth to eighth European intensive care unit patient suffers from an underlying malignant disease. A large proportion of these patients present with cancer-related complications. This review explains why the prognosis of critically il...
Theresa Westphal,Gabriel Rinnerthaler,Brigitte Mlineritsch
Theresa Westphal
The probability of developing breast cancer increases with age. Therefore, more than 50 % of women with breast cancer are older than 65 years at the time of diagnosis. However, elderly patients are often undertreated and clinical trials for...